🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Ultrasound-Guided Extracorporeal Shock Wave Therapy for Calcific Tendinitis

RecruitingNAAges 20 Years - 70 YearsAllTaipei Medical University WanFang Hospital
NCT07756307 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Calcific tendinitis of the shoulder is a debilitating musculoskeletal condition that significantly impacts the working-age population, typically those between 30 and 60 years of age. Accounting for approximately 7- 17% of shoulder pain complaints, it is characterized by the pathological deposition of calcium hydroxyapatite crystals within the rotator cuff tendons, most notably the supraspinatus. The progression of the disease, particularly during the resorptive phase described in Uhthoff's cycle, is associated with a dramatic increase in intratendinous pressure and severe inflammatory pain, leading to substantial functional impairment and socioeconomic burden. While Extracorporeal Shock Wave Therapy (ESWT) is a well established non-invasive modality known to promote calcific resorption via cavitation effects and mechanotransduction-induced neovascularization, its clinical efficacy remain

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age between 20 and 70 years * Unilateral calcific tendinitis of the shoulder confirmed by clinical physical examination, including a positive Neer's impingement test * Symptom duration of more than 3 months * Imaging (radiography and/or high-resolution ultrasound) demonstrating a calcific deposit within a rotator cuff tendon with a maximal diameter greater than 5 mm * Baseline self-reported pain intensity greater than 4 on the Visual Analog Scale (VAS, 0-10) * Willing and able to provide written informed consent Exclusion Criteria: * Concomitant full-thickness rotator cuff tear * History of fracture or surgery involving the ipsilateral shoulder * Coagulopathy, or anticoagulant therapy that cannot be safely discontinued * Pregnancy or breastfeeding * Malignancy, particularly involving or adjacent to the shoulder region * Local infection or skin lesion at the intended treatment site * Injection therapy to the ipsilateral shoulder within the preceding 6 weeks * Any other condition that, in the judgment of the investigator, makes the participant unsuitable for participation in the trial
💊

What it tests

  • Ultrasound guide localization
  • Palpation localization
📍

Where

1 site
Wan Fang Hospital, Taipei Medical University
Taipei, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy